CAR T-Cell Therapy
Advertisement
Despite the successes of chimeric antigen receptor (CAR) T-cell therapy against hematologic malignancies, toxicities continue ...
Chimeric antigen receptor (CAR) T-cell therapy has been very effective against a growing number of hematologic malignancies, ...
A recent letter to Bone Marrow Transplantation describes results of a survey that aimed to capture the impact of the COVID-19 ...
Malignant mesothelioma is a treatment-resistant type of cancer that starts in the mesothelial lining of the pleura or the ...
An article appearing in the journal Therapeutic Advances in Infectious Disease called for research to explore the infectious ...
A recent article in the journal Biomedicines reviewed the potential of chimeric antigen receptor (CAR) T-cell therapy in ...
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of multiple myeloma, but the disease is still ...
Chimeric antigen receptor (CAR) T-cell therapy is a promising new option for treatment of hematologic malignancies, but many ...
Chimeric antigen receptor (CAR) T-cell therapy has provided a novel, effective treatment option for patients with relapsed or ...
Early research did not show that chimeric antigen receptor (CAR) T-cell therapy is effective against lung cancer, a solid ...
Immune effector cell–associated neurotoxicity syndrome is a clinical and neuropsychiatric syndrome that can occur in the ...
Targeted immunotherapy is a very promising strategy in the treatment of multiple myeloma.
Researchers Explore Safety and Efficacy of BCMA CAR T-Cell Therapy in Patients with Multiple Myeloma
Chimeric antigen receptor (CAR) T-cell immunotherapy has shown great promise against hematologic malignancies. Therefore, the ...
Chimeric antigen receptor (CAR) T-cell therapy is a rapidly emerging treatment option for patients with B-cell malignancies. ...
A chimeric antigen receptor (CAR) T-cell therapy induced high response rates in a cohort of patients with indolent ...
The autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel induced responses in ...
Study results showed a durable response and acceptable safety profile in patients with Hodgkin lymphoma.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.